Related Experiment Videos
Sulphasalazine induced agranulocytosis.
The New Zealand Medical Journal
|July 13, 1983
Summary
Two patients developed agranulocytosis, a serious condition, after taking sulphasalazine (Salazopyrin). Fortunately, both individuals recovered fully from this adverse drug reaction.
Area of Science:
- Pharmacology
- Hematology
- Clinical Medicine
Background:
- Sulfasalazine is a medication used to treat inflammatory conditions like rheumatoid arthritis and ulcerative colitis.
- Agranulocytosis is a severe, potentially life-threatening condition characterized by a sharp drop in white blood cells, increasing infection risk.
Observation:
- Two distinct cases of sulphasalazine-induced agranulocytosis were observed within a short timeframe.
- Both patients presented with symptoms indicative of severe neutropenia.
Findings:
- The reported cases confirm sulphasalazine as a potential cause of drug-induced agranulocytosis.
- Prompt recognition and discontinuation of the offending drug led to complete recovery in both patients.
Implications:
- This report highlights the importance of monitoring for hematological adverse effects during sulphasalazine therapy.
- Clinicians should maintain a high index of suspicion for agranulocytosis in patients presenting with relevant symptoms while on sulphasalazine.
- Awareness of this rare but serious side effect is crucial for patient safety and effective management.